Previous 10 | Next 10 |
Planned Subgroup Analysis of RAMP 201 Data Showed Combination Demonstrated Robust Efficacy in Recurrent LGSOC Regardless of Number and Class of Prior Therapies Including After Poor Response to Prior Therapy Late-Breaking Abstract Featured as an Oral Presentation during a Plenary Session a...
Verastem Inc. (VSTM) is expected to report $-0.92 for Q3 2023
2023-10-26 16:25:17 ET More on Verastem Verastem: Signs Of Life For A Beaten-Down Equity RAMPing Up Hope: Verastem's Cancer Crusade Verastem, China's GenFleet to collaborate on RAS pathway-driven cancer drugs Seeking Alpha’s Quant Rating on Verastem ...
Mike Crowther Appointed Chief Commercial and Business Strategy Officer David Mitchell Appointed Senior Vice President, Head of Regulatory Affairs Dan Calkins Promoted to Chief Financial Officer from Vice President of Finance Verastem Oncology (Nasdaq: VSTM) (the “...
Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve Patients No New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to Moderate Enrollment of Patient...
2023-10-04 21:00:20 ET Summary Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pathway activation, with promising early results in r...
2023-10-02 03:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovarian Cancer Efficacy Data Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific...
2023-09-12 23:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-09-03 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 ® and Russell Microcap ...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...